Novavax, Inc. (NVAX) — closed signal from March 11, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 9, 2026.
Predicted vs. what happened
What happened
Reached 28% of the predicted growth at its peak, without hitting the target.
The thesis — published March 11, 2026
Novavax looks interesting for a short trade because recent events changed the story. The company unexpectedly returned to profit and signed a licensing deal with Pfizer, giving a clear business reason for the stock to rise. That said, news about vaccine rules or approvals can move the stock fast, so buying is best on calm pullbacks rather than chasing spikes.
Primary drivers
- Company returned to profit, improving its story and outlook
- Deal with Pfizer gives extra commercial opportunities
- Price testing the breakout area gives clearer risk control
- Better vaccine sentiment can make investors value shares higher
How it played out
NVAX: target was not reached
Lyra published NVAX on 2026-03-11 as a short-term trade at $10.88. The thesis expected 24% growth to $13.49. It pointed to a return to profit, a Pfizer licensing deal, a breakout-area test, and better vaccine sentiment as reasons the stock could rise.
Inside the window from 2026-03-11 to 2026-06-09, NVAX peaked at $11.61 on 2026-05-27, a 6.7% gain. It stayed below the $13.49 target. The stock ended at $8.67. The thesis only partially played out: there was a modest rise, but it never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.